Showing 2861-2870 of 4063 results for "".
- Flying Eye Hospital Celebrates 20 Years of Eye Care in Ethiopia this World Sight Dayhttps://modernod.com/news/flying-eye-hospital-celebrates-20-years-of-eye-care-in-ethiopia-this-world-sight-day/2479789/The Orbis Flying Eye Hospital—the world’s only U.S.-accredited teaching hospital on board an MD-10 aircraft—has returned to Addis Ababa to conduct a 3-week training project from October 1-19, 2018, invited by the Federal Ministr
- Ophthotech Completes Patient Recruitment for Its Phase 2b Clinical Trial of Zimura for Geographic Atrophy Secondary to Dry AMDhttps://modernod.com/news/ophthotech-completes-patient-recruitment-for-its-phase-2b-clinical-trial-of-zimura-for-geographic-atrophy-secondary-to-dry-amd/2479816/Ophthotech announced completion of patient recruitment for its phase 2b clinical trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, monotherapy in patients with geographic atrophy secondary to dry age-related macular degeneration (AMD). Complement factor C5
- EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrantshttps://modernod.com/news/eyepoint-pharmaceuticals-announces-proceeds-of-28-9-million-from-exercised-warrants/2479829/EyePoint Pharmaceuticals announced that the company has received proceeds of $28.9 million from the exercise of warrants by EW Healthcare Partners, Rosalind Advisors, and another accredited investor (Second Tranche Investors). “We are pleased to receive the continued support of EW Healthc
- Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trialhttps://modernod.com/news/aldeyra-therapeutics-announces-positive-results-from-phase-2b-dry-eye-disease-clinical-trial/2479841/Aldeyra Therapeutics announced positive results from its phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease. “The early onset and broad activity observed in the phase 2b clinical trial sugg
- Novartis to Cut Over 2000 Jobs in Switzerland, UKhttps://modernod.com/news/novartis-to-cut-over-2000-jobs-in-switzerland-uk/2479850/Novartis announced that it will slash more than 2,000 jobs by 2022, including eliminating 1,700 positions in Switzerland and around 400 roles in the UK, as it looks to increase profitability. The move comes as the company consolidates manufacturing and shifts positions elsewhere as part of plans
- Ellex 2RT Retinal Rejuvenation Effective for Select Cases of Intermediate AMDhttps://modernod.com/news/ellex-2rt-retinal-rejuvenation-effective-for-select-cases-of-intermediate-amd/2479852/Ellex Medical Lasers Limited announced the results of the Ellex 2RT Laser Intervention in Age-Related Macular Degeneration (LEAD) multicenter clinical trial. The results of the trial were published in Ophthalmology. According to researchers involved in the LEAD trial, Ellex’s 2RT
- Positive PEACHTREE Data to be Highlighted at Euretina 2018https://modernod.com/news/positive-peachtree-data-to-be-highlighted-at-euretina-2018/2479871/Clearside Biomedical announced that data from PEACHTREE, its pivotal phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be presented by Ron Neumann, MD, Uveitis Specialist at Maccabi Health Services, Tel Aviv, Israel and co-Chair of
- Market Scope: Ophthalmic Laser Market Expected to Total $400 Million in 2018https://modernod.com/news/market-scope-ophthalmic-laser-market-expected-to-total-400-million-in-2018/2479885/Global revenues for ophthalmic lasers—photocoagulation, photodisruption (YAG), and SLT—along with maintenance, accessories, and endoprobes, will total more than $400 million in 2018 and grow
- SightMD, 24-Location Ophthalmology Group, and Chicago Pacific Founders Set Partnershiphttps://modernod.com/news/sightmd-24-location-ophthalmology-group-and-chicago-pacific-founders-set-partnership/2479899/SightMD, a provider of eyecare services through 24 locations, and Chicago Pacific Founders Fund LP, a health care investment fund, announced that they are entering into a partnership to expand SightMD’s patient-centric care model to patients, providers, and payers across the New York, New Jersey
- Roche’s Genentech Unit to Cut 223 Jobs in UShttps://modernod.com/news/roches-genentech-unit-to-cut-223-jobs-in-us/2479930/Roche’s Genentech unit plans to cut 223 jobs from its South San Francisco, California headquarters by the end of the year. The company, which disclosed the staff reductions in a Worker Adjustment and Retraining Notification (WARN) posted by the State of California’s Employment Develop